2 The Pii Formula, Dosage Form Focus, August 23
2 The Pii Formula, Dosage Form Focus, August 23
This month, The Formula explores dosage forms. While oral solid dosage continues to dominate the market, other viable and lucrative options, such as liquid formulations, present exciting opportunities. We also go behind the scenes at Pii to see how the formulation team was able to develop a new dosage form for a rare disease indication. And, we look forward to receiving your questions and feedback at urana@pharm-int.com.
Main Feature: OSDs – The OG in Drug Formulation
Our long history with oral solid dosage formulations has given rise to an ever-growing pharmaceutical market. Recent developments are taking oral solid dosage solutions to new heights. Innovation is being driven by the need to differentiate and to deliver sustainable, advanced products in a crowded pharmaceutical space.
Read More to learn about the latest trends.
CDMO Insights: Dosage Form Focus – Oral Solutions & Suspensions: The Art of Pharmacy
Experts agree that liquid formulations are a viable and lucrative alternative to pills, tablets, and capsules that are difficult to take for some patient populations. But, there are challenges associated with liquid dosage.
Find Out how formulating the right oral liquid dosage form in early-stage development depends on the art of pharmacy.
Project Feature: Creating a New Dosage Form from an Approved Drug for a New Rare Disease Indication
A pharmaceutical company, developing a molecule for another indication, discovered side effects during clinical trials that might mitigate or even cure a rare hereditary blood disorder. The initial clinical work began for the rare blood disorder, but due to various unexpected circumstances, the program was never completed.
Learn How Pii’s formulation, analytical, and regulatory teams worked to file an IND within just 14 days.
Q&A: Do you have a question for the Pii formulation team?
Submit your questions to us at urana@pharm-int.com and see them answered in a future edition of The Formula.
Interested in more on Oral Drug Development: Check out our Oral Dosage eBook
or contact Umber if you have questions about your oral products: urana@pharm-int.com.
Cindy H. Dubin, editor of The Formula
Cindy H. Dubin is an award-winning journalist who has been reporting on the bio/pharmaceutical industry for more than 20 years. Her published work includes formulation development, manufacturing, drug delivery, QA/QC, cell and gene therapy, and more.
